Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| LIGAND PHARMACEUTICALS INCLGND · Entity 3825 | Director | June 05, 2026 | June 09, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
LIGAND PHARMACEUTICALS INC
Report date June 05, 2026 · Filed June 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 8,930 |
Reported balance
After 2026-06-05 transaction · row 1
1 source rowRow 1 · 2026-06-05 · Grant · Acquired 836 · Balance 8,930 F1: Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 5, 2026. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant. |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $237.00 · Expires 2036-06-05 | Direct | 2,938 |
Reported balance
After 2026-06-05 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-05 · Grant · Acquired 2,938 · Balance 2,938 F2: Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 5, 2026. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 5, 2026. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant.
F2: Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 5, 2026. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 05, 2026 Filed Jun 9, 2026 23:35 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 2,938 | $0.00 Strike: $237.00 | $0.00 |
DisclosureSEC source: 0002001011-26-000096 · edgardoc.xml · derivative · entry 2 Gray Nancy Ryan · CIK 0001714949 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,938 Underlying: Common Stock · 2,938 shares Expires 2036-06-05 F2 · derivative.exercise_date: Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 5, 2026. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant. Read SEC document |
| June 05, 2026 Filed Jun 9, 2026 23:35 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantCommon Stock | 836 | $0.00 | $0.00 |
DisclosureSEC source: 0002001011-26-000096 · edgardoc.xml · nonDerivative · entry 1 Gray Nancy Ryan · CIK 0001714949 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,930 F1 · shares: Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 5, 2026. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant. Read SEC document |
| November 07, 2025 Filed Nov 12, 2025 21:45 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 3,015 | $0.00 Strike: $73.57 | $0.00 |
DisclosureSEC source: 0002001011-25-000098 · edgardoc.xml · derivative · entry 6 Gray Nancy Ryan · CIK 0001714949 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,015 shares Expires 2027-08-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This Option was previously reported as a Grant of 3,452 shares, which vested in full on August 18, 2020, at an exercise price of $126.2600 per share but was adjusted pursuant to the OmniAb Inc. separation from the issuer. Read SEC document |
| November 07, 2025 Filed Nov 12, 2025 21:45 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 3,556 | $0.00 Strike: $66.19 | $0.00 |
DisclosureSEC source: 0002001011-25-000098 · edgardoc.xml · derivative · entry 5 Gray Nancy Ryan · CIK 0001714949 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,556 shares Expires 2029-06-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This Option was previously reported as a Grant of 4,071 shares, which vested in full on June 06, 2020, at an exercise price of $113.5900 per share but was adjusted pursuant to the OmniAb Inc. separation from the issuer. Read SEC document |
| November 07, 2025 Filed Nov 12, 2025 21:45 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 3,015 | $205.45 | $619,431.75 |
DisclosureSEC source: 0002001011-25-000098 · edgardoc.xml · nonDerivative · entry 4 Gray Nancy Ryan · CIK 0001714949 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,094 Read SEC document |
| November 07, 2025 Filed Nov 12, 2025 21:45 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionCommon Stock | 3,015 | $73.57 | $221,813.55 |
DisclosureSEC source: 0002001011-25-000098 · edgardoc.xml · nonDerivative · entry 3 Gray Nancy Ryan · CIK 0001714949 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,109 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 07, 2025 Filed Nov 12, 2025 21:45 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 3,556 | $205.45 | $730,580.20 |
DisclosureSEC source: 0002001011-25-000098 · edgardoc.xml · nonDerivative · entry 2 Gray Nancy Ryan · CIK 0001714949 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,094 Read SEC document |
| November 07, 2025 Filed Nov 12, 2025 21:45 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionCommon Stock | 3,556 | $66.19 | $235,371.64 |
DisclosureSEC source: 0002001011-25-000098 · edgardoc.xml · nonDerivative · entry 1 Gray Nancy Ryan · CIK 0001714949 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,650 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 06, 2025 Filed Jun 10, 2025 23:39 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 5,783 | $0.00 Strike: $105.99 | $0.00 |
DisclosureSEC source: 0002001011-25-000046 · edgardoc.xml · derivative · entry 2 Gray Nancy Ryan · CIK 0001714949 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,783 Underlying: Common Stock · 5,783 shares Expires 2035-06-06 F2 · derivative.exercise_date: Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 6, 2025. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant. Read SEC document |
| June 06, 2025 Filed Jun 10, 2025 23:39 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantCommon Stock | 1,209 | $0.00 | $0.00 |
DisclosureSEC source: 0002001011-25-000046 · edgardoc.xml · nonDerivative · entry 1 Gray Nancy Ryan · CIK 0001714949 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,094 F1 · shares: Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 6, 2025. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant. Read SEC document |
| June 14, 2024 Filed Jun 19, 2024 01:26 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 5,444 | $0.00 Strike: $80.06 | $0.00 |
DisclosureSEC source: 0002001011-24-000056 · edgardoc.xml · derivative · entry 2 Gray Nancy Ryan · CIK 0001714949 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,444 Underlying: Common Stock · 5,444 shares Expires 2034-06-14 F2 · derivative.exercise_date: Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 14, 2024. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant. Read SEC document |
| June 14, 2024 Filed Jun 19, 2024 01:26 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantCommon Stock | 1,252 | $0.00 | $0.00 |
DisclosureSEC source: 0002001011-24-000056 · edgardoc.xml · nonDerivative · entry 1 Gray Nancy Ryan · CIK 0001714949 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,885 F1 · shares: Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 14, 2024. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant. Read SEC document |
| May 09, 2024 Filed May 18, 2024 00:00 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 934 | $83.20 | $77,713.38 |
DisclosureSEC source: 0002001011-24-000054 · edgardoc.xml · nonDerivative · entry 1 Gray Nancy Ryan · CIK 0001714949 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,633 F1 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $83.1100 to $83.2650. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 09, 2023 Filed Jun 13, 2023 22:55 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 5,461 | $0.00 Strike: $73.76 | $0.00 |
DisclosureSEC source: 0000886163-23-000043 · edgardoc.xml · derivative · entry 2 Gray Nancy Ryan · CIK 0001714949 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,461 Underlying: Common Stock · 5,461 shares Expires 2033-06-09 F2 · derivative.exercise_date: Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 9, 2023. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant. Read SEC document |
| June 09, 2023 Filed Jun 13, 2023 22:55 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantCommon Stock | 1,142 | $0.00 | $0.00 |
DisclosureSEC source: 0000886163-23-000043 · edgardoc.xml · nonDerivative · entry 1 Gray Nancy Ryan · CIK 0001714949 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,567 F1 · shares: Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 9, 2023. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant. Read SEC document |
| December 22, 2022 Filed Dec 27, 2022 23:31 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 3,050 | $0.00 Strike: $67.03 | $0.00 |
DisclosureSEC source: 0000899243-22-039409 · doc4.xml · derivative · entry 1 Gray Nancy Ryan · CIK 0001714949 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,050 Underlying: Common Stock · 3,050 shares Expires 2032-12-22 F1 · derivative.exercise_date: Grant to reporting person of stock options that will vest and become exercisable on December 22, 2023. Read SEC document |
| June 10, 2022 Filed Jun 13, 2022 22:46 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 4,340 | $0.00 Strike: $79.29 | $0.00 |
DisclosureSEC source: 0000886163-22-000081 · edgardoc.xml · derivative · entry 2 Gray Nancy Ryan · CIK 0001714949 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,340 Underlying: Common Stock · 4,340 shares Expires 2032-06-10 F2 · derivative.exercise_date: Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 10, 2022. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant. Read SEC document |
| June 10, 2022 Filed Jun 13, 2022 22:46 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantCommon Stock | 1,004 | $0.00 | $0.00 |
DisclosureSEC source: 0000886163-22-000081 · edgardoc.xml · nonDerivative · entry 1 Gray Nancy Ryan · CIK 0001714949 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,706 F1 · shares: Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 10, 2022. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant. Read SEC document |
| June 04, 2021 Filed Jun 8, 2021 01:24 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 3,269 | $0.00 Strike: $115.39 | $0.00 |
DisclosureSEC source: 0000886163-21-000091 · edgardoc.xml · derivative · entry 2 Gray Nancy Ryan · CIK 0001714949 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,269 Underlying: Common Stock · 3,269 shares Expires 2031-06-04 F2 · derivative.exercise_date: Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 04, 2021. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant. Read SEC document |
| June 04, 2021 Filed Jun 8, 2021 01:24 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantCommon Stock | 630 | $0.00 | $0.00 |
DisclosureSEC source: 0000886163-21-000091 · edgardoc.xml · nonDerivative · entry 1 Gray Nancy Ryan · CIK 0001714949 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,702 F1 · shares: Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 04, 2021. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant. Read SEC document |
| June 10, 2020 Filed Jun 12, 2020 22:34 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 2,468 | $0.00 Strike: $117.58 | $0.00 |
DisclosureSEC source: 0000886163-20-000077 · edgardoc.xml · derivative · entry 2 Gray Nancy Ryan · CIK 0001714949 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,468 Underlying: Common Stock · 2,468 shares Expires 2030-06-10 F2 · derivative.exercise_date: Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 10, 2020. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant. Read SEC document |
| June 10, 2020 Filed Jun 12, 2020 22:34 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantCommon Stock | 831 | $0.00 | $0.00 |
DisclosureSEC source: 0000886163-20-000077 · edgardoc.xml · nonDerivative · entry 1 Gray Nancy Ryan · CIK 0001714949 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,072 F1 · shares: Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 10, 2020. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant. Read SEC document |
| June 06, 2019 Filed Jun 7, 2019 22:52 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 4,071 | $0.00 Strike: $113.59 | $0.00 |
DisclosureSEC source: 0000886163-19-000106 · edgardoc.xml · derivative · entry 2 Gray Nancy Ryan · CIK 0001714949 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,071 Underlying: Common Stock · 4,071 shares Expires 2029-06-06 F2 · derivative.exercise_date: Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 06, 2019. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant. Read SEC document |
| June 06, 2019 Filed Jun 7, 2019 22:52 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantCommon Stock | 835 | $0.00 | $0.00 |
DisclosureSEC source: 0000886163-19-000106 · edgardoc.xml · nonDerivative · entry 1 Gray Nancy Ryan · CIK 0001714949 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,241 F1 · shares: Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 06, 2019. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant. Read SEC document |
| June 19, 2018 Filed Jun 21, 2018 20:45 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 2,474 | $0.00 Strike: $76.77 | $0.00 |
DisclosureSEC source: 0000899243-18-017608 · doc4.xml · derivative · entry 2 Gray Nancy Ryan · CIK 0001714949 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,474 Underlying: Common Stock · 2,474 shares Expires 2028-06-18 F1 · derivative.exercise_date: Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 19, 2018. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant. Read SEC document |
| June 19, 2018 Filed Jun 21, 2018 20:45 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantCommon Stock | 493 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-017608 · doc4.xml · nonDerivative · entry 1 Gray Nancy Ryan · CIK 0001714949 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,406 F1 · shares: Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 19, 2018. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant. Read SEC document |
| June 19, 2018 Filed Jul 3, 2018 22:43 UTC Amendment | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 2,474 | $0.00 Strike: $195.91 | $0.00 |
DisclosureSEC source: 0000886163-18-000098 · edgardoc.xml · derivative · entry 1 Gray Nancy Ryan · CIK 0001714949 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,474 Underlying: Common Stock · 2,474 shares Expires 2028-06-18 F1 · derivative.exercise_price: This amendment is being filed to correct the exercise price listed in item 2 of Table II in order to reflect the market closing price on the grant date. F2 · derivative.exercise_date: Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 19, 2018. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant. Read SEC document |
| August 18, 2017 Filed Aug 22, 2017 16:50 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantCommon Stock · Derivative | 3,452 | $0.00 Strike: $126.26 | $0.00 |
DisclosureSEC source: 0000886163-17-000106 · wf-form4_150342057116504.xml · derivative · entry 2 Gray Nancy Ryan · CIK 0001714949 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,452 Underlying: Common Stock · 3,452 shares Expires 2027-08-18 F1 · security: Non-Qualified Stock Option (right to buy) F2 · derivative.exercise_date: The option becomes exercisable in 3 successive equal annual installments upon completion of each calendar year of service beginning on the grant date. Read SEC document |
| August 18, 2017 Filed Aug 22, 2017 16:50 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantCommon Stock | 913 | $0.00 | $0.00 |
DisclosureSEC source: 0000886163-17-000106 · wf-form4_150342057116504.xml · nonDerivative · entry 1 Gray Nancy Ryan · CIK 0001714949 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 913 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.